Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17869392 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2RECQLNR1H2MEN1 | |
| SCHEMBL17869750 | 0.82 | USP2 (0.43) | USP2SMN1; SMN2RECQLNR1H2MEN1 | |
| SCHEMBL31094785 | 0.81 | USP2 (0.44) | USP2SMN1; SMN2RECQLNR1H2MEN1 | |
| SCHEMBL20356529 | 0.80 | USP2 (0.42) | USP2SMN1; SMN2RECQLNR1H2MEN1 | |
| SCHEMBL2332025 | 0.79 | USP2 (0.40) | USP2SMN1; SMN2RECQLNR1H2MEN1 | |
| SCHEMBL21381853 | 0.79 | NAMPT (0.33) | — | |
| SCHEMBL20354930 | 0.79 | USP2 (0.38) | USP2SMN1; SMN2RECQLMAPTJAK2 | |
| SCHEMBL22799172 | 0.78 | USP2 (0.51) | USP2SMN1; SMN2RECQLALDH1A1MAPT | |
| SCHEMBL25187478 | 0.78 | USP2 (0.41) | USP2SMN1; SMN2RECQLNR1H2MEN1 | |
| SCHEMBL23107340 | 0.78 | RECQL (0.46) | USP2SMN1; SMN2RECQLALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119731179-A | IKZF2 degradation agent and application thereof | 密歇根大学董事会 | 2025-03-28 | — | — | CN | disclosed |
| EP-4499649-A1 | IKZF2 DEGRADERS AND USES THEREOF | Regents of the University of Michigan (US) | 2025-02-05 | — | — | EP | disclosed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| WO-2023183540-A1 | IKZF2 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2014008223-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | IKZF1, IKZF2, IKZF3 | USP2 251/4885SMN1; SMN2 2807/4885RECQL 3095/4885 |
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | USP2 4401/4885SMN1; SMN2 4320/4885RECQL 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.